These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 7493234)
21. Latanoprost for uncontrolled glaucoma in a compassionate case protocol. Patelska B; Greenfield DS; Liebmann JM; Wand M; Kushnick H; Ritch R Am J Ophthalmol; 1997 Sep; 124(3):279-86. PubMed ID: 9439353 [TBL] [Abstract][Full Text] [Related]
22. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Camras CB Ophthalmology; 1996 Jan; 103(1):138-47. PubMed ID: 8628544 [TBL] [Abstract][Full Text] [Related]
23. Latanoprost : an update of its use in glaucoma and ocular hypertension. Perry CM; McGavin JK; Culy CR; Ibbotson T Drugs Aging; 2003; 20(8):597-630. PubMed ID: 12795627 [TBL] [Abstract][Full Text] [Related]
24. Efficacy of the dorzolamide/timolol fixed combination versus latanoprost in the treatment of ocular hypertension or glaucoma: combined analysis of pooled data from two large randomized observer and patient-masked studies. Fechtner RD; McCarroll KA; Lines CR; Adamsons IA J Ocul Pharmacol Ther; 2005 Jun; 21(3):242-9. PubMed ID: 15969642 [TBL] [Abstract][Full Text] [Related]
25. Reduction of IOP with latanoprost. Hoste AM Ophthalmology; 1997 Jun; 104(6):895-7. PubMed ID: 9186420 [No Abstract] [Full Text] [Related]
26. Effect of topical latanoprost 0.005% on intraocular pressure and pupil diameter in normal and glaucomatous cats. McDonald JE; Kiland JA; Kaufman PL; Bentley E; Ellinwood NM; McLellan GJ Vet Ophthalmol; 2016 Jul; 19 Suppl 1(Suppl 1):13-23. PubMed ID: 26183373 [TBL] [Abstract][Full Text] [Related]
27. Circadian IOP-lowering efficacy of travoprost 0.004% ophthalmic solution compared to latanoprost 0.005%. García-Feijoo J; Martínez-de-la-Casa JM; Castillo A; Méndez C; Fernández-Vidal A; García-Sánchez J Curr Med Res Opin; 2006 Sep; 22(9):1689-97. PubMed ID: 16968572 [TBL] [Abstract][Full Text] [Related]
28. A 12-week, randomized, double-masked study of fixed combination latanoprost/timolol versus latanoprost or timolol monotherapy. Palmberg P; Kim EE; Kwok KK; Tressler CS; Eur J Ophthalmol; 2010; 20(4):708-18. PubMed ID: 20099236 [TBL] [Abstract][Full Text] [Related]
29. Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study. Katz LJ; Rauchman SH; Cottingham AJ; Simmons ST; Williams JM; Schiffman RM; Hollander DA Curr Med Res Opin; 2012 May; 28(5):781-8. PubMed ID: 22458918 [TBL] [Abstract][Full Text] [Related]
31. A pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol. Hedman K; Alm A Eur J Ophthalmol; 2000; 10(2):95-104. PubMed ID: 10887918 [TBL] [Abstract][Full Text] [Related]
32. A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension. Schachar RA; Raber S; Courtney R; Zhang M Curr Eye Res; 2011 Sep; 36(9):809-17. PubMed ID: 21851167 [TBL] [Abstract][Full Text] [Related]
33. Comparison of the intraocular pressure lowering effect of latanoprost and a fixed combination of timolol-pilocarpine eye drops in patients insufficiently controlled with beta adrenergic antagonists. French Latanoprost Study Group, and the Swedish Latanoprost Study Group. Nordmann JP; Söderström M; Rouland JF; Malecaze F Br J Ophthalmol; 2000 Feb; 84(2):181-5. PubMed ID: 10655195 [TBL] [Abstract][Full Text] [Related]
34. Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension. Lewis RA; Levy B; Ramirez N; Kopczynski CC; Usner DW; Novack GD; Br J Ophthalmol; 2016 Mar; 100(3):339-44. PubMed ID: 26209587 [TBL] [Abstract][Full Text] [Related]
35. Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension. Day DG; Hollander DA Curr Med Res Opin; 2008 May; 24(5):1435-42. PubMed ID: 18402717 [TBL] [Abstract][Full Text] [Related]
36. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Noecker RS; Dirks MS; Choplin NT; Bernstein P; Batoosingh AL; Whitcup SM; Am J Ophthalmol; 2003 Jan; 135(1):55-63. PubMed ID: 12504698 [TBL] [Abstract][Full Text] [Related]
37. Latanoprost and brimonidine: therapeutic and physiologic assessment before and after oral nonsteroidal anti-inflammatory therapy. Sponsel WE; Paris G; Trigo Y; Pena M; Weber A; Sanford K; McKinnon S Am J Ophthalmol; 2002 Jan; 133(1):11-8. PubMed ID: 11755835 [TBL] [Abstract][Full Text] [Related]
38. Intraocular pressure lowering effect of brinzolamide 1.0% as adjunctive therapy to latanoprost 0.005% in patients with open angle glaucoma or ocular hypertension: an uncontrolled, open-label study. Shoji N; Ogata H; Suyama H; Ishikawa H; Suzuki H; Morita T; Kawai H; Nishimoto H; Nemoto T; Shimizu K Curr Med Res Opin; 2005 Apr; 21(4):503-8. PubMed ID: 15899098 [TBL] [Abstract][Full Text] [Related]
39. A comparative study of two dose regimens of latanoprost in patients with elevated intraocular pressure. Lusky M; Ticho U; Glovinsky J; Weinberger D; Nesher R; Yassur Y; Melamed S Ophthalmology; 1997 Oct; 104(10):1720-4. PubMed ID: 9331215 [TBL] [Abstract][Full Text] [Related]
40. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study. Mishima HK; Masuda K; Kitazawa Y; Azuma I; Araie M Arch Ophthalmol; 1996 Aug; 114(8):929-32. PubMed ID: 8694726 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]